Pharvaris (PHVS)
(Delayed Data from NSDQ)
$19.51 USD
-1.58 (-7.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $19.38 -0.13 (-0.67%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.51 USD
-1.58 (-7.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $19.38 -0.13 (-0.67%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
by Zacks Equity Research
Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
by Zacks Equity Research
Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
by Zacks Equity Research
Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
Wall Street Analysts Predict an 88.24% Upside in Pharvaris N.V. (PHVS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at an 88.2% upside potential for Pharvaris N.V. (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Henry Schein (HSIC) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.
Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AllScripts Healthcare (MDRX) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year.